Artemis Investment Management LLP Grows Position in Repligen Corporation (NASDAQ:RGEN)

Artemis Investment Management LLP lifted its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 110.1% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 323,229 shares of the biotechnology company's stock after purchasing an additional 169,397 shares during the period. Artemis Investment Management LLP owned about 0.58% of Repligen worth $41,128,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Vanguard Group Inc. increased its holdings in Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC raised its position in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after buying an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC grew its position in shares of Repligen by 3.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after buying an additional 32,665 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of RGEN stock opened at $124.21 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. The business has a fifty day moving average of $128.22 and a 200 day moving average of $141.22. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of -276.02, a price-to-earnings-growth ratio of 3.55 and a beta of 1.10. Repligen Corporation has a 1 year low of $102.97 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm's revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 earnings per share. As a group, research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on RGEN. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Royal Bank Of Canada reduced their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. Finally, Barclays began coverage on Repligen in a report on Tuesday. They issued an "overweight" rating and a $150.00 price objective for the company. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $172.83.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.